Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Becton Dickinson Shuffles Executive Management; Biocept Appoints New Directors


Becton Dickinson disclosed during its fiscal fourth quarter and full-year earnings call several changes to its executive leadership.

Tom Polen has been promoted to the role of group president for the Medical Surgical Systems and Preanalytical-Pharmaceutical Systems business units. Polen had most recently served as president of Diagnostic Systems and before that, president of Preanalytical Systems.

Linda Tharby has also been promoted to the role of group president for Biosciences and Preanalytical Systems. Tharby had most recently been president of Diabetes Care, and prior to that, served as vice president and general manager in Pharmaceutical Systems after serving as country general manager in Canada.

Meantime, Alberto Mas is assuming Polen's responsibilities in Diagnostic Systems. Mas had most recently served as president of BD Biosciences for the past two years. Prior to that, he served as worldwide president for Medical Surgical Systems in BD Medical for six years.

Finally, BD said during the call that Claude Dartiguelongue will assume all responsibilities previously held by Mas as president of BD Biosciences. Dartiguelongue previously served as president of Pharmaceutical Systems since October 2009.

Biocept this week announced the appointment of Marsha Chandler and Bruce Huebner as independent directors.

Chandler is currently executive vice president and COO of the Salk Institute for Biological Studies. She previously served as senior vice chancellor for academic affairs at the University of California, San Diego. She is a fellow of the Royal Society of Canada, and received her PhD from the University of North Carolina, Chapel Hill.

Huebner is managing director of LynxCom Partners, and is chairman of the board of Vermillion. Previously he served as president and CEO of TrovaGene, and president of Osmetech Molecular Diagnostics (now part of GenMark Diagnostics). Huebner also previously served as president and COO of Nanogen, and executive vice president and chief officer of Gen-Probe (now part of Hologic).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.